News Release
View printer-friendly version
|
<< Back |
ZUG,
SunTrust Robinson Humphrey 5th Annual Life Sciences Summit
Date: Wednesday, May 8, 2019
Location: New
Date: Wednesday, May 15, 2019
Presentation: 1:00 p.m. PT
Location: Las Vegas, NV
Date: Tuesday, May 21, 2019
Presentation: 11:00 a.m. ET
Location:
A live webcast of the
About
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge,
CRISPR Investor Contact:
susan.kim@crisprtx.com
CRISPR Media Contact:
WCG on behalf of CRISPR
347-658-8290
jpaganelli@wcgworld.com
Source: CRISPR Therapeutics AG